Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.39 |
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533171 | 0.91 | GHSR (0.40) | GHSRCYP51A1DPP4FAPDPP8 | |
| SCHEMBL867707 | 0.91 | GHSR (0.40) | GHSRCYP51A1DPP4FAPDPP8 | |
| SCHEMBL867706 | 0.91 | GHSR (0.40) | GHSRCYP51A1DPP4FAPDPP8 | |
| SCHEMBL10039187 | 0.85 | GHSR (0.40) | GHSRDPP4FAPDPP8DPP9 | |
| SCHEMBL13374464 | 0.85 | GHSR (0.39) | GHSRCYP51A1DPP4FAPDPP8 | |
| SCHEMBL868545 | 0.84 | GHSR (0.57) | GHSRCYP51A1DPP4OPRD1 | |
| SCHEMBL868544 | 0.84 | GHSR (0.57) | GHSRCYP51A1DPP4OPRD1 | |
| SCHEMBL867917 | 0.82 | GHSR (0.53) | GHSRCYP51A1MMEPYGLHPGD | |
| SCHEMBL867918 | 0.82 | GHSR (0.53) | GHSRCYP51A1MMEPYGLHPGD | |
| SCHEMBL867608 | 0.82 | GHSR (0.45) | GHSRCYP51A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | GIPR, GHSR, GLP1R | GHSR 2/4885CYP51A1 2303/4885DPP4 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.